• 1
    O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 2002; 360: 11191125.
  • 2
    Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112: 352364.
  • 3
    Fellström B. Risk factors for and management of post-transplantation cardiovascular disease. BioDrugs 2001; 15: 261278.
  • 4
    McDiarmid S. The necessity for steroid induction or long-term maintenance after liver transplantation: the argument against. Transplant Proc 1998; 30: 14491451.
  • 5
    European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423428.
  • 6
    The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 11101115.
  • 7
    Pirenne J, Aerts R, Koshiba T, Van Gelder F. Roskams T, Schetz M, et al. Steroid-free immunosuppression during and after liver transplantation–a 3-yr follow-up report. Clin Transplant 2003; 17: 177182.
  • 8
    Ringe B, Braun F, Schutz E, Fuzesi L, Lorf T, Canelo R, et al. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation 2001; 71: 508515.
  • 9
    Carswell CI, Plosker GL, Wagstaff AJ. Daclizumab: a review of its use in the management of organ transplantation. BioDrugs 2001; 15: 745773.
  • 10
    Mühlbacher F, European Liver Transplantation Tacrolimus vs Cyclosporin Microemulsion Study Group. Tacrolimus versus cyclosporin microemulsion in liver transplantation: results of a 3-month study. Transplant Proc 2001; 33: 13391340.
  • 11
    Reding R, Feyaerts A, Vraux H, Latinne D, de la Parra B, Cornet A, et al. Prophylactic immunosuppression with anti-interleukin-2 receptor monoclonal antibody LO-Tact-1 versus OKT3 in liver allografting. A two-year follow-up study. Transplantation 1996; 61: 14061409.
  • 12
    Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation 1997; 64: 17551760.
  • 13
    Baden L, Katz J. Infectious disease issues in the well transplant patient. Graft 2001; 4: 276289.
  • 14
    Chisholm MA. Issues of adherence to immunosuppressant therapy after solid-organ transplantation. Drugs 2002; 62: 567575.
  • 15
    Matas AJ, Humar A, Gillingham KJ, Payne WD, Gruessner RWG, Kandaswamy R, et al. Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. Kidney Int 2002; 62: 704714.
  • 16
    Boillot O, Viale JP, Gratadour P, Meeus P, Souraty P, Le Derf Y, et al. Reversal of early acute rejection with increased doses of tacrolimus in liver transplantation. A pilot study. Transplantation 1998; 68: 11821185.